目的 探討水飛薊賓聯(lián)合復方二氯醋酸二異丙胺治療非酒精性脂肪肝的臨床療效。方法 選取2015年9月-2016年6月在駐馬店市中心醫(yī)院進行治療的86例非酒精性脂肪肝患者，根據(jù)治療方案不同分為對照組（43例）和治療組（43例）。對照組患者口服復方二氯醋酸二異丙胺片，2片/次，3次/d。治療組在對照組的基礎(chǔ)上口服水飛薊賓膠囊，3粒/次，3次/d。兩組患者均連續(xù)治療8周。觀察兩組患者的臨床療效，同時比較兩組治療前后肝功能、血脂水平和血清學指標變化情況。結(jié)果 治療后，對照組和治療組總有效率分別為72.09%和88.37%，兩組總有效率比較差異有統(tǒng)計學意義（P<0.05）。治療后，兩組患者三酰甘油（TG）、膽固醇（TC）及丙氨酸轉(zhuǎn)氨酶（ALT）和天氨酸轉(zhuǎn)氨酶（AST）水平均顯著降低，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且治療組降低程度優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。與治療前相比，治療后兩組血清腫瘤壞死因子-α（TNF-α）、白細胞介素-18（IL-18）及降鈣素原（PCT）均明顯降低，IL-10則明顯升高，同組治療前后比較差異有統(tǒng)計學意義（P<0.05）；且治療組上述指標改善程度優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結(jié)論 水飛薊賓聯(lián)合復方二氯醋酸二異丙胺治療非酒精性脂肪肝效果顯著，可明顯改善患者肝功能及血脂水平，并降低機體炎癥反應(yīng)，具有一定的臨床推廣應(yīng)用價值。

Objective To investigate the clinical efficacy of silibinin combined with compound diisopropylamine dichloroacetate in treatment of non-alcoholic fatty liver. Methods Patients (86 cases) with non-alcoholic fatty liver in Zhumadian Central Hospital from September 2015 to June 2016 were divided into the control (43 cases) and treatment (43 cases) groups based on different treatments. Patients in the control group were po administered with Compound Diisopropylamine Dichloroacetate Tablets, 2 tablets/time, three times daily. Patients in the treatment group were po administered with Silibinin Capsules on the basis of control group, 3 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and blood lipid, liver function and serological indexes before and after treatment in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment group were 72.09% and 88.37%, respectively, and there were differences between two groups (P<0.05). After treatment, TG, TC, ALT, and AST levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the decrease degree of these indicators in the treatment group was better than that in the control group, with significant difference between two groups (P<0.05). And compared with those before treatment, TNF-α, IL-18, and PCT levels in two groups were significantly decreased, and IL-10 was significantly increased, and the difference was statistically significant in the same group (P<0.05). And these observation indexes in the treatment group were better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Silibinin combined with compound diisopropylamine dichloroacetate has a significant therapeutic effect in treatment of non-alcoholic fatty liver, can significantly improve the liver function and blood lipid level, and reduce the inflammatory reaction, which has a certain clinical application value.